Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009896 | 1.00 | PPARA (0.61) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL376018 | 1.00 | PPARA (0.61) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL13702217 | 0.95 | PPARA (0.56) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL13702216 | 0.95 | PPARA (0.56) | PPARAPPARGACEPPARDKLK7 | |
| Dioxane SCHEMBL27814606 | 0.93 | PPARA (0.54) | PPARAPPARGACEPPARDKLK7 | |
| SCHEMBL8177426 | 0.93 | PPARA (0.58) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL8178286 | 0.93 | PPARA (0.58) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL1517760 | 0.93 | PPARA (0.55) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL13007476 | 0.93 | PPARA (0.55) | PPARAPPARGACEKLK7KLK5 | |
| SCHEMBL2011835 | 0.93 | PPARA (0.55) | PPARAPPARGACEKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108912007-B | Preparation method of dexchloroglutamine | 中国农业科学院兰州畜牧与兽药研究所 | 2021-02-26 | — | — | CN | claimed |
| WO-2025027624-A1 | CYCLIC GLYCOLIPOPEPTIDE VACCINE ADJUVANTS AND THE PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2025-02-06 | — | — | WO | disclosed |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2023-11-30 | — | — | US | disclosed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| EP-0259084-B1 | CRYSTALLINE N-(S-3-METHYLHEPTANOYL)-D-GAMMA-GLUTAMYL-GLYCYL-D-ALANINE, AND PROCESSES AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| CN-1017436-B | PEPTIDE CONTAINING IMMUNOEXCITANT | PFIZER (US) | 1992-07-15 | — | — | CN | disclosed |
| US-4767743-A | ANTIINFECTION AGENTS | PFIZER INC. (US) | 1988-08-30 | — | — | US | disclosed |
| WO-1988001613-A1 | CRYSTALLINE N-(S-3-METHYLHEPTANOYL)-D-GAMMA-GLUTAMYL-GLYCYL-D-ALANINE, AND PROCESSES AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1988-03-10 | — | — | WO | disclosed |
| WO-1988001612-A1 | PROCESSES AND INTERMEDIATES FOR N-(S-3-ALKYL-HEPTANOYL)-D-GAMMA-GLUTAMYL-GLYCYL-D-ALANINE | PFIZER INC. (US) | 1988-03-10 | — | — | WO | disclosed |
| EP-0259084-A2 | Crystalline N-(S-3-methylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine, and processes and intermediates therefor | PFIZER INC. (US) | 1988-03-09 | — | — | EP | disclosed |
| CN-87105898-A | N-(sProcess and intermediates for the preparation of -3-alkylheptanoyl -D-r-glutamyl -glycyl -D-alanyl | — | 1988-03-09 | — | — | CN | disclosed |
| EP-0258032-A2 | Processes and intermediates for N-(S-3-alkylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine | PFIZER INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| EP-0227306-A2 | Peptide immunostimulants | PFIZER INC. (US) | 1987-07-01 | — | — | EP | disclosed |
| CN-86107931-A | PEPTIDE CONTAINING IMMUNOEXCITANT | — | 1987-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | PPARA 3022/4885PPARG 3826/4885ACE 1509/4885 |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PPARA 2055/4885PPARG 1047/4885ACE 3916/4885 |
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | NOD2, TLR7, TLR9 | PPARA 868/4885PPARG 323/4885ACE 4544/4885 |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PPARA 1776/4885PPARG 903/4885ACE 4062/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | PPARA 3022/4885PPARG 3826/4885ACE 1509/4885 |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PPARA 2026/4885PPARG 1010/4885ACE 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.